We report a first-in-humans clinical study of EPR oximetry using the OxyChip to establish its feasibility and utility for clinically useful tumor oxygen measurements in cancer patients. Repeated measurements from a cohort of 11 cancer patients in 33 sessions over a long period of time revealed variable levels of clinically significant hypoxia as well as variable responses to a hypoxia-mitigation intervention. Overall, in light of this variability, this study further underscores the need to provide individualized repeatable assessment of tumor oxygenation in the context of planned hyperoxygenation interventions to optimize clinical outcomes.
This abstract and the presentation materials are available to members only; a login is required.